Latest News in the pharma Industry

Research & Development

GlycoMimetics poster shows GMI-1271 reverses drug resistance in multiple myeloma models

GlycoMimetics poster shows GMI-1271 reverses drug resistance in multiple myeloma models

6 Dec 2015

GlycoMimetics to initiate myeloma trial in mid-2016.

Read more 
Amgen's first biosimilar marketing authorization application submitted to EMA for ABP 501

Amgen's first biosimilar marketing authorization application submitted to EMA for ABP 501

4 Dec 2015

Supported by Phase III studies in moderate-to-severe plaque psoriasis and moderate-to-severe rheumatoid arthritis.

Read more 
Propeller Health announces development agreement and R&D collaboration with GSK to develop a digital sensor for the Ellipta inhaler

Propeller Health announces development agreement and R&D collaboration with GSK to develop a digital sensor for the Ellipta inhaler

1 Dec 2015

Collaboration reinforces Propeller Health's leadership in respiratory digital health and creates a joint opportunity to advance treatment of respiratory disease through digital innovation.

Read more 
Novozymes' Veltis half-life extension technology embraced by Paras Biopharmaceuticals to develop new biobetter

Novozymes' Veltis half-life extension technology embraced by Paras Biopharmaceuticals to develop new biobetter

30 Nov 2015

Paras Biopharmaceuticals partners with Novozymes in a feasibility study using Veltis technology to develop an improved version of a leading osteoporosis treatment.

Read more 
GSK announces start of Phase III study of sirukumab in giant cell arteritis

GSK announces start of Phase III study of sirukumab in giant cell arteritis

30 Nov 2015

Study approach will specifically answer whether treatment with sirukumab can reduce the duration of steroid treatment typical in clinical practice.

Read more 
Sosei subsidiary Heptares to collaborate with Pfizer on GPCR targets across multiple therapeutic areas

Sosei subsidiary Heptares to collaborate with Pfizer on GPCR targets across multiple therapeutic areas

30 Nov 2015

Pfizer will be responsible for developing and commercialising any potential therapeutic agents (small molecules or biologics derived from StaR antigens) for each target and will have exclusive global rights to any potential resulting agents.

Read more 
ReproCELL acquires Biopta to expand its drug discovery services

ReproCELL acquires Biopta to expand its drug discovery services

27 Nov 2015

Acquisition aimed at strengthening ReproCELL’s pharmaceutical industry-targeted drug discovery services.

Read more 
Epigenomics appeals recent FDA request for additional information

Epigenomics appeals recent FDA request for additional information

27 Nov 2015

Company believes that an approval for the intended use of Epi proColon is warranted based on the data that has been submitted to date.

Read more 
BMS announces regulatory update for Opdivo in advanced melanoma

BMS announces regulatory update for Opdivo in advanced melanoma

27 Nov 2015

Read more 
Amgen's first biosimilar Biologics License Application for ABP 501 submitted To FDA

Amgen's first biosimilar Biologics License Application for ABP 501 submitted To FDA

26 Nov 2015

Supported by Phase III studies in moderate-to-severe plaque psoriasis and moderate-to-severe rheumatoid arthritis.

Read more 
Allergan and Rugen Therapeutics collaborate to discover and develop ground-breaking medicines to treat ASD and OCD

Allergan and Rugen Therapeutics collaborate to discover and develop ground-breaking medicines to treat ASD and OCD

25 Nov 2015

The companies have identified and will advance novel, first-in-class small molecules to treat major unmet needs in neurology and psychiatry.

Read more 
Idera to collaborate with GSK to identify third generation antisense molecules for treatment of renal disease

Idera to collaborate with GSK to identify third generation antisense molecules for treatment of renal disease

24 Nov 2015

Idera is eligible to receive approximately $100 million in development and regulatory milestone payments, including a $2.5 million upfront payment.

Read more